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and coaxial subendothelial SMCs. This is a remarkable and
ingenious scientific feat.
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The poor availability of usable autogenous conduit for
vascular bypass grafting remains a significant clinical problem.
Less than half of all patients requiring lower extremity bypass
grafting can be reconstructed using appropriately sized, disease-
free, single-segment greater saphenous vein. This has long
prompted the search for an operative strategy wherein, instead
of harvesting autologous veins or implanting prosthetics, use-
able vascular conduits can be “grown” in a laboratory in the days
prior to elective revascularization. Such “tissue-engineered”
conduits are the subject of the study conducted by Quint et al
and reported herein.
In a series of bench top and animal experiments, human
tissue engineered vessels (hTEV) were grown using a process
employing human aortic smooth muscle cells (SMCs), biode-
gradable scaffolds, biomimetic perfusion, and decellularization.
After creation in vitro, the hTEVs were implanted as aortic
interposition grafts in nude rats and found to have acceptable
6-week patency (83%) without evidence of aneurysm formation
or rupture. When explanted and examined, the decellularized
hTEVs were found to have recruited a confluent endotheliumOf course, a myriad of issues must be addressed prior to
onsideration of clinical application of hTEVs. First and foremost
s the certain immunogenicity of conduits created using heterolo-
ous human tissue, immunogenicity that was not observed in this
xperiment given the use of nude hosts. Decellularization could be
xpected to attenuate immunologic responses to the level of toler-
nce, perhaps, but even low levels of chronic antigenicity may
egatively affect patency. The logistical practicalities of the ap-
roach also loom large, as the consistent creation of acceptable
onduits is obviously a highly specialized and technical endeavor.
o we really envision a time when personalized surgical “spare
arts” are routinely available in clinical practice? It seems more
ikely that conduits such as these will be created in a central,
ommercial laboratory and distributed to hospitals in a similar
ashion as currently available medical devices. Thus, the “personal”
ature of such devices will likely be limited.
These shortcomings notwithstanding, Quint and colleagues
ffer a provocative and inventive solution to the ubiquitous prob-
em of small-diameter, long-segment vascular conduit availability.
t is hoped that this group will refine their process and technique,
xtend these initial experimental observations, and swiftly advance
o the clinical phase of development.
